Condition: Colorectal Cancer · Sponsor: Neogap Therapeutics AB
This is an open-label, non-randomised FIH trial investigating the safety and tolerability of a novel ATMP, pTTL, composed of autologous tumour-draining lymph node-derived T cells stimulated in vitro with personalised cancer neoantigens. The neoantigens are selected through a process starting with next generation sequencing (NGS) of tumour material from the patient followed by selection of neoantigenic mutations using an in-house software, PIOR®. Selected neoantigen epitopes are expressed as recombinant proteins, NAG, and used to stimulate T cells to promote neoantigen-specific T cell expansion in vitro in pTTL production. pTTL is thus based on autologous cells stimulated with patient-specific neoantigens. In consequence, every pTTL product is unique and designated for use in one single individual. pTTL will be administered to patients with stage IV colorectal cancer (CRC) as a single intravenous dose.
This description comes directly from the study's public registry record.
Samuel Svensson, PhD · +46 73 354 21 94 · samuel.svensson@neogap.se
Andrea Salmén, MSE · +46 70 359 57 11 · andrea.salmen@neogap.se
Always discuss trial participation with your own doctor first.
| Medical Unit Cell therapy and Allogeneic Stem cell Transplantation (ME CAST), and the Center for Clinical Cancer studies - Phase 1 unit, Karolinska University Hospital | Stockholm, Stockholm County, Sweden | Recruiting |
| Unit for Colorectal Surgery, Dept. of Surgery, Västmanlands Sjukhus Västerås | Västerås, Västerås, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05908643